Cardiotoxicity of the cancer therapeutic agent imatinib mesylate by Kerkelä Risto, Grazette Luanda, Yacobi Rinat, Iliescu Cezar, Patten Richard, Beahm Cara, Walters Brian, Shevtsov Sergei, Pesant Stéphanie, Clubb Fred J, Rosenzweig Anthony, Salomon Robert N, Van Etten Richard A, Alroy Joseph, Durand Jean-Bernard, Force Thomas in Nature medicine (2006).

[PMID: 16862153] PubMed


Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction. Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy. With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death. Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death. Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.